Chugai acquires Romark's nitazoxanide for Japan
This article was originally published in Scrip
Executive Summary
Roche's Japanese subsidiary Chugai has acquired exclusive development, manufacturing and commercialisation rights in Japan to Romark Laboratories' antiviral agent nitazoxanide, for the indication of hepatitis C.